Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
Holding CMRX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.25Last Year’s EPS
-$0.2Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 196.04%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
The call highlighted significant progress in clinical studies and a strong financial position, despite the increased research expenses and net loss. The positive developments in the pipeline and financial management outweigh the challenges.Company Guidance
During the Chimerix third quarter 2024 earnings call, the company provided guidance on several key metrics. The Phase III ACTION study of Dordaviprone is progressing well, with enrollment continuing in 15 countries and a prespecified interim safety review recommending no changes to the study's conduct. This study features two treatment arms, both administering a 625-milligram dose, with one arm administering the dose twice weekly. The company is also nearing the completion of Phase I dose escalation studies for ONC206. Financially, Chimerix reported a net loss of $22.9 million for the quarter, with research and development expenses increasing to $19.6 million, primarily due to the ACTION study. General and administrative expenses decreased significantly to $5.2 million. The company ended the quarter with over $152 million in cash and cash equivalents, providing a cash runway into the fourth quarter of 2026. Additionally, Chimerix is preparing for the potential commercialization of Dordaviprone, with a forecasted global market opportunity of over $750 million, and is planning to file an NDA for provisional approval in Australia by year-end.Progress in Phase III ACTION Study
Continued enrollment in the global Phase III ACTION study of Dordaviprone, with a positive interim safety review from the Data Monitoring Committee recommending the study continue with no changes.
Nearing Completion of Phase I Dose Escalation Studies
The Phase I dose escalation studies for ONC206 are nearing completion, with the compound showing a well-tolerated profile in adult and pediatric patients.
Financial Position and Cash Runway
Chimerix ended the third quarter with over $152 million in cash and cash equivalents, providing a cash runway extending into the fourth quarter of 2026.
Decreased General and Administrative Expenses
General and administrative expenses decreased significantly to $5.2 million from $9.3 million in the same period in 2023.
---
CMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $1.01 | $0.94 | -6.93% |
| Aug 13, 2024 | $0.82 | $0.77 | -6.10% |
| May 01, 2024 | $0.94 | $0.95 | +1.06% |
| Feb 29, 2024 | $1.24 | $1.15 | -7.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Chimerix (CMRX) report earnings?
Chimerix (CMRX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Chimerix (CMRX) earnings time?
Chimerix (CMRX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMRX EPS forecast?
CMRX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.25.
---